HK1198180A1 - 岩藻糖基化缺陷型細胞 - Google Patents

岩藻糖基化缺陷型細胞

Info

Publication number
HK1198180A1
HK1198180A1 HK14112533.3A HK14112533A HK1198180A1 HK 1198180 A1 HK1198180 A1 HK 1198180A1 HK 14112533 A HK14112533 A HK 14112533A HK 1198180 A1 HK1198180 A1 HK 1198180A1
Authority
HK
Hong Kong
Prior art keywords
fucosylation
deficient cells
deficient
cells
Prior art date
Application number
HK14112533.3A
Other languages
English (en)
Inventor
Gang Chen
Darya Burakov
James P Fandl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198180A1 publication Critical patent/HK1198180A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271GDP-L-fucose synthase (1.1.1.271)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK14112533.3A 2009-06-02 2012-05-07 岩藻糖基化缺陷型細胞 HK1198180A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US34885810P 2010-05-27 2010-05-27

Publications (1)

Publication Number Publication Date
HK1198180A1 true HK1198180A1 (zh) 2015-03-13

Family

ID=42338231

Family Applications (3)

Application Number Title Priority Date Filing Date
HK14112533.3A HK1198180A1 (zh) 2009-06-02 2012-05-07 岩藻糖基化缺陷型細胞
HK12104409.3A HK1163745A1 (zh) 2009-06-02 2012-05-07 岩藻糖基化缺陷細胞
HK18109072.2A HK1249547A1 (zh) 2009-06-02 2018-07-12 鹽藻糖基化欠缺細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK12104409.3A HK1163745A1 (zh) 2009-06-02 2012-05-07 岩藻糖基化缺陷細胞
HK18109072.2A HK1249547A1 (zh) 2009-06-02 2018-07-12 鹽藻糖基化欠缺細胞

Country Status (17)

Country Link
US (8) US8409838B2 (zh)
EP (3) EP3279326B1 (zh)
JP (4) JP5744856B2 (zh)
KR (2) KR101641526B1 (zh)
CN (1) CN102459603B (zh)
AU (1) AU2010256753B2 (zh)
BR (1) BRPI1010035A2 (zh)
CA (1) CA2764370C (zh)
DK (3) DK2808393T3 (zh)
ES (2) ES2527173T3 (zh)
HK (3) HK1198180A1 (zh)
HU (1) HUE038596T2 (zh)
IL (1) IL216624A (zh)
PL (3) PL2808393T3 (zh)
SG (1) SG176251A1 (zh)
TW (1) TWI513818B (zh)
WO (1) WO2010141478A1 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
CA2829110C (en) 2011-03-06 2019-01-15 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US20160251410A1 (en) 2013-09-03 2016-09-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US20150093782A1 (en) * 2013-10-01 2015-04-02 The University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins
KR102399005B1 (ko) 2014-03-11 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 항-egfrviii 항체 및 그것의 용도
KR20170012286A (ko) * 2014-05-30 2017-02-02 뉴 잉글랜드 바이오랩스, 인크 탈당화 시약 및 방법
CA2954534C (en) * 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3371206B1 (en) * 2015-11-02 2021-04-14 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
MX2018008447A (es) 2016-01-06 2019-05-30 Oncobiologics Inc Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
JP7134868B2 (ja) 2016-04-20 2022-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 発現強化座位の使用に基づく抗体を作製するための組成物および方法
AU2017253241A1 (en) * 2016-04-20 2018-09-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
CA3110254C (en) * 2018-08-29 2023-08-29 United Biopharma Inc Afucosylated antibodies and manufacture thereof
JPWO2020090747A1 (ja) 2018-10-29 2021-11-25 株式会社 免疫生物研究所 抗hiv抗体及びその製造方法
IL298194A (en) 2020-05-26 2023-01-01 Regeneron Pharma Antibodies against sars-cov2-spike glycoprotein and antigen-binding fragments
WO2021247779A1 (en) 2020-06-03 2021-12-09 Regeneron Pharmaceuticals, Inc. METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
KR20240024061A (ko) 2021-06-22 2024-02-23 리제너론 파마슈티칼스 인코포레이티드 항-EGFRvIII 항체 약물 접합체 및 이의 용도
TW202321292A (zh) 2021-07-14 2023-06-01 美商再生元醫藥公司 抗sars-cov-2-棘醣蛋白抗體及抗原結合片段
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
US20230287043A1 (en) 2022-03-02 2023-09-14 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2785941C (en) * 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
US6919183B2 (en) 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
JP2008541770A (ja) 2005-06-03 2008-11-27 ジェネンテック・インコーポレーテッド 改変したフコシル化レベルを有する抗体の産生方法
PL2059536T3 (pl) 2006-08-14 2014-07-31 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
SG187521A1 (en) 2007-03-07 2013-02-28 Glycofi Inc Production of glycoproteins with modified fucosylation
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2010018847A1 (ja) 2008-08-13 2010-02-18 協和発酵キリン株式会社 遺伝子組換えプロテインs組成物
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
CA2829110C (en) 2011-03-06 2019-01-15 Merck Serono S.A. Low fucose cell lines and uses thereof

Also Published As

Publication number Publication date
PL2808393T3 (pl) 2018-04-30
TWI513818B (zh) 2015-12-21
WO2010141478A1 (en) 2010-12-09
EP2438171A1 (en) 2012-04-11
CA2764370A1 (en) 2010-12-09
KR101441437B1 (ko) 2014-09-25
HUE038596T2 (hu) 2018-10-29
US20230295583A1 (en) 2023-09-21
CN102459603B (zh) 2013-11-06
KR20120029443A (ko) 2012-03-26
EP3279326A1 (en) 2018-02-07
US20130164786A1 (en) 2013-06-27
US20190024129A1 (en) 2019-01-24
KR20140039340A (ko) 2014-04-01
DK3279326T3 (da) 2020-12-21
IL216624A (en) 2015-02-26
PL3279326T3 (pl) 2021-03-08
JP6211642B2 (ja) 2017-10-11
US20210254022A1 (en) 2021-08-19
BRPI1010035A2 (pt) 2015-08-25
CA2764370C (en) 2018-08-21
EP2808393B1 (en) 2018-01-10
US20170211115A1 (en) 2017-07-27
AU2010256753B2 (en) 2013-11-28
US20160090410A1 (en) 2016-03-31
HK1163745A1 (zh) 2012-09-14
KR101641526B1 (ko) 2016-07-21
US11560550B2 (en) 2023-01-24
EP2808393A3 (en) 2015-03-11
JP2015051021A (ja) 2015-03-19
US8409838B2 (en) 2013-04-02
TW201107469A (en) 2011-03-01
ES2527173T3 (es) 2015-01-21
JP2012528594A (ja) 2012-11-15
PL2438171T3 (pl) 2015-04-30
DK2808393T3 (en) 2018-03-12
CN102459603A (zh) 2012-05-16
EP2438171B1 (en) 2014-12-17
ES2661074T3 (es) 2018-03-27
IL216624A0 (en) 2012-02-29
US20100304436A1 (en) 2010-12-02
SG176251A1 (en) 2011-12-29
EP3279326B1 (en) 2020-10-14
US9206455B2 (en) 2015-12-08
EP2808393A2 (en) 2014-12-03
US9550823B2 (en) 2017-01-24
AU2010256753A1 (en) 2012-01-12
US20200080124A1 (en) 2020-03-12
JP2016104045A (ja) 2016-06-09
DK2438171T3 (en) 2015-01-26
JP2017006147A (ja) 2017-01-12
JP5744856B2 (ja) 2015-07-08
HK1249547A1 (zh) 2018-11-02
US10006070B2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
HK1249547A1 (zh) 鹽藻糖基化欠缺細胞
GB0908613D0 (en) T Cell Reseptors
EP2475029A4 (en) BATTERY
EP2416373A4 (en) SOLAR CELL
EP2457078A4 (en) NANOFLUIDIC CELL
PT3121928T (pt) Elemento de pilha de zinco-ar
HK1147350A1 (en) Photovoltaic cell
EP2356697A4 (en) SOLAR CELL
EP2371008A4 (en) SOLAR CELL
GB201017421D0 (en) Cell
EP2508411A4 (en) STRUCTURE
EP2467882A4 (en) SOLAR CELL
EP2441107A4 (en) THIN BATTERY
EP2386124A4 (en) SOLAR CELL
EP2395565A4 (en) SOLAR CELL
GB0913469D0 (en) Cell support
GB0920775D0 (en) Cells
EP2500948A4 (en) SOLAR CELL
ZA201107671B (en) Photovoltaic cell
GB0917143D0 (en) Cell stack
HUE052153T2 (hu) Fukoziláció-deficiens sejtek
GB0901675D0 (en) Cells
GB0908223D0 (en) Cells
GB0920035D0 (en) Cell
TWI372482B (en) Battery